<DOC>
	<DOCNO>NCT01074047</DOCNO>
	<brief_summary>The purpose study compare effect azacitidine ( Vidaza ) conventional care regimens overall survival elderly AML patient .</brief_summary>
	<brief_title>Study Vidaza Versus Conventional Care Regimens Treatment Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Diagnosis one follow Newly diagnose de novo acute myeloid leukemia ( AML ) AML secondary myelodysplastic syndrome ( MDS ) AML secondary exposure leukemogenic therapy agent primary malignancy remission least 2 year Bone marrow blast &gt; 30 % Age â‰¥ 65 year Easter Cooperative Oncology Group ( ECOG ) 02 Previous cytotoxic biologic treatment AML ( except hydroxyurea ) Previous treatment azacitidine , decitabine cytarabine Prior use target therapy agent ( e.g. , FLT3 inhibitor , kinase inhibitor ) AML French American British subtype ( FAB M3 ) AML associate inv ( 16 ) , ( 8 ; 21 ) , ( 16 ; 16 ) , ( 15:17 ) , ( 9 ; 22 ) karyotype Prior bone marrow stem cell transplantation Candidate allogeneic bone marrow stem cell transplant Diagnosis malignant disease within previous 12 month ( exclude base cell carcinoma , `` insitu '' carcinoma cervix breast local malignancy excise irradiated high probability cure ) Malignant hepatic tumor Uncontrolled systemic infection Active viral infection Human Immunodeficiency Virus ( HIV ) Hepatitis type B C Use experimental drug therapy within 28 day prior Day 1</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Vidaza</keyword>
	<keyword>azacitidine</keyword>
	<keyword>Intensive Chemotherapy</keyword>
	<keyword>Low Dose Cytarabine</keyword>
	<keyword>Celgene</keyword>
</DOC>